Clarity develops a non-invasive neuromodulation headset designed to influence brain rhythms associated with neurodegenerative disease. The company’s approach uses synchronized light and sound stimulation delivered through a wearable device. Its platform is intended to engage neural circuits implicated in cognitive decline without surgical intervention. Clarity positions its technology within regulated clinical research and therapeutic development contexts.

The technology delivers rhythmic audiovisual stimulation at 40 Hz, a frequency associated with gamma-band neural activity. By entraining brain rhythms through sensory pathways, the system aims to modulate neural network function linked to cognition and memory. This approach does not rely on direct electrical stimulation or invasive recording, instead leveraging patterned sensory input to influence neural dynamics. The headset is designed for repeated use under controlled protocols.

Clarity targets neurological conditions such as Alzheimer’s disease and related disorders where disruptions in brain rhythms are implicated. The platform is intended for use within clinical trials and therapeutic evaluation rather than consumer wellness. Its focus reflects growing interest in non-invasive neuromodulation strategies that aim to restore network-level brain function through rhythmic stimulation.